We have assembled a leading team across top-tier institutions.
Dr. Colgan is the Director of the Mucosal Inflammation Program and Vice Chairman of the Department of Medicine at the University of Colorado. Dr. Colgan’s research focuses on the identification of novel anti-inflammatory molecules associated with mucosal inflammation. He is one of world’s leading experts on Specialized Proresolving Mediators (SPMs), having served on the faculty at Harvard Medical School in the Center for Experimental Therapeutics under the tutelage of Dr. Charles Serhan, who created the modern field of resolution biology. Dr. Colgan has published more than 170 original papers, served as a Section Editor for the Journal of Immunology, and is a standing member of the GMPB study section at the NIH. He is the previous chairman of the Research Fellowship Award study section for the CCFA and presently serves as the chairman of the CCFA Senior Research Award study section.
Dr. Asma Nusrat is a leading research clinician in the field of epithelial wound healing in the context of inflammatory bowel disease (IBD). Asma trained and became certified in Anatomic Pathology at the Brigham and Women’s Hospital (BWH)/Harvard Medical School after which she completed a fellowship in Gastrointestinal and Hepatobiliary pathology, as well as a postdoctoral research fellowship in epithelial cell biology at the same institution. While at BWH, she began investigating fundamental mechanisms of epithelial barrier regulation and wound repair. During this time, she was successful in obtaining NIH funding, advancing from NRSA to K08 grants and rose to the rank of Assistant Professor. She left BWH to join the faculty at Emory University to continue developing a highly successful research program centered on mucosal pathobiology in the gut, training fellows and graduate students and performing clinical service as a gastrointestinal pathologist. At Emory, Asma was highly successful in obtaining multiple NIH grants while remaining clinically active in gastrointestinal surgical pathology. She rapidly rose through the ranks and was promoted to professor with tenure in 2007. In 2015, Asma left Emory to join the faculty in the department of pathology at the University of Michigan where she was appointed as the Aldred Scott Warthin Professor and Director of Experimental Pathology.
In her lab, Asma continues a long standing quest to elucidate the pathologic mechanisms of chronic inflammatory diseases of the gut and mucosal wound repair. She has published more than 150 papers, many in high profile journals, regularly speaks at national and international symposia related to her field, and has served as an Associate Editor for leading journals in the field for over a decade. In addition to her robust research program, Asma remains clinically active as a practicing Gastrointestinal and Liver Pathologist while enjoying mentoring and teaching graduate and medical students, residents, postdoctoral fellows and junior faculty.
Charles Nicholas Serhan is the Simon Gelman Professor of Anaesthesia (Biochemistry and Molecular Pharmacology) at Harvard Medical School and also Professor of Oral Medicine, Infection and Immunity at Harvard School of Dental Medicine; He is Director of the Center for Experimental Therapeutics and Reperfusion Injury at Brigham and Women’s Hospital. Dr. Serhan’s pioneering studies on the chemistry-medicine interface have resulted in the discovery of the Specialized Pro-resolving Mediators (SPMs), a super-family of biochemical mediators that actively orchestrate the resolution of inflammation and provide the molecular underpinnings for a new era in inflammation resolution pharmacology.
Charles received a BS in biochemistry from Stony Brook University followed by a Doctorate in experimental pathology and medical sciences from New York University School of Medicine. He was a visiting scientist and post-doctoral fellow at the Karolinska Institutet, Stockholm with Professor Bengt Samuelsson (Nobel Laurate Medicine 82). In 1987, he joined the faculty at Harvard Medical School and received an honorary degree from Harvard University (1996).
He has received several awards including an NIH MERIT award and has delivered > 50 keynote and plenary lectures. Among these recent awards are: the 2008 William Harvey Outstanding Scientist Medal and AAAS Fellow in 2011. In 2010, he received the Society for Leukocyte Biology Bonazinga Award, The American College of Rheumatology Hench (Nobel Laurate) Award Lecture in 2011 presented by the Mayo Clinic Hench Society, and Mérieux 2013 Laureate.
In 2016, he received the IUBMB Lecture Metal and the Ross Prize in Molecular Medicine. Recently, he received the International Eicosanoid Research Foundation’s 2017 Lifetime Achievement Award and the American Society of Investigative Pathology 2018 Rous Whipple Award and the 2018 Gaddum International Prize and Award Lecture from the British Pharmacology Society.
Inflammatory Bowel Disease
Dr. Hanauer is an internationally recognized expert on the treatment of inflammatory bowel disease. He currently serves as the medical director of the Digestive Disease Center at Northwestern University Feinberg School of Medicine and as the Clifford Joseph Barborka Professor of Medicine. After earning his medical degree from the University of Illinois, Dr. Hanauer completed his internship and residency in internal medicine followed by a fellowship in gastroenterology at the University of Chicago. There Dr. Hanauer was mentored by one of the great clinicians in American gastroenterology, the legendary Dr. Joseph B. Kirsner. Dr. Hanauer held a Professorship in Medicine at Chicago named for Dr. Kirsner.
As Chairman of the Gastrointestinal Drugs Advisory Committee at the US Food and Drug Administration, Dr. Hanauer authored the FDA’s “Guidelines for Clinical Evaluation of Drugs for Patients with Inflammatory Bowel Disease”. From 2014-2015, he served as president of the American College of Gastroenterology (ACG), where he has been a member of the ACG Board of Trustees since 2006, an officer of the ACG since 2010 and a contributing committee member since 1989. He has represented the ACG at the FDA related to development of end-points for IBD in a series of “GREAT” meetings. He edited Nature Reviews Gastroenterology & Hepatology and chaired the ACG Finance Committee from 2011 to 2012. Dr. Hanauer has also held leadership positions in the American Gastroenterological Association (AGA) as chair of the Sections on Infection, Immunology and Inflammatory Bowel Disease as well as Clinical Practice, and served on the AGA Governing Board as a Counselor for Clinical Research. Internationally, he is a member of the European Crohn’s and Colitis Organization (ECCO) and is a former chairman of the International Organization for IBD (IOIBD).
Dr. Hanauer was awarded the AGA Fiterman Foundation Joseph B. Kirsner Award in Gastroenterology in 2001 and the AGA Janssen Award for Clinical Excellence in GI in 2004. He is currently an Associate Editor for Clinical Gastroenterology and Hepatology. In addition, Dr. Hanauer has worked with the American Board of Internal Medicine serving on the Gastroenterology sub-specialty. He has also held leadership positions within the Crohn’s & Colitis Foundation of American and in 2011 received CCFA’s Scientific Achievement Award for Clinical Research. Over the course of his career, Hanauer has authored or co-authored hundreds of peer-reviewed journal articles, books, book chapters, monographs, and editorials.
Dr. Hyams is one of the world’s leading experts in pediatric inflammatory bowel disease (IBD) including Crohn’s disease and ulcerative colitis. As Head of the Division of Digestive Diseases, Hepatology, and Nutrition at Connecticut Children’s Medical Center, he has led pivotal clinical trials for therapeutic agents in IBD and directed a long-term natural history registry that has described the course of almost 2000 children newly diagnosed with IBD. Dr. Hyams is the recent recipient of a $10.4M grant from the National Institutes of Health investigating the response of children newly diagnosed with ulcerative colitis to standardized therapies. He has worked with the FDA developing endpoints for pediatric clinical trials, has published more than 250 peer reviewed articles, and is the co-editor of one of the standard pediatric digestive disease textbooks, Pediatric Gastrointestinal and Liver Disease. Dr. Hyams was the first pediatrician to ever receive the prestigious Scientific Achievement in IBD Clinical Research Award from the Crohn’s & Colitis Foundation of America. He graduated from University of Pennsylvania School of Medicine and conducted his residency and fellowship at Boston Children’s Hospital.
Dr. Joshua R. Korzenik, one of the leading IBD researchers and key opinion leaders in the country, is director of the Brigham & Women’s Hospital Crohn’s and Colitis Center and assistant professor at Harvard Medical School. Dr. Korzenik has been involved in IBD research and care of patients for almost 25 years, with his research focusing on 1) translational research in IBD and 2) investigating environmental influences in IBD, with a focus on their common nexus of the intestinal microbiome. Dr. Korzenik is the author of almost 60 peer-reviewed articles and research papers. He speaks frequently at professional meetings and is an active member of many professional committees. Dr. Korzenik has been the principal investigator of over a dozen research projects, ranging from studies of diet and probiotics to international comparisons of IBD. Dr. Korzenik earned his bachelor’s degree from Harvard College in 1980 and his medical degree from Albert Einstein College of Medicine in the Bronx, New York, in 1987. He was a resident at Harvard-affiliated Beth Israel Deaconess Hospital in Boston from 1987 to 1990 and fellow in gastroenterology and clinical epidemiology at Yale University School of Medicine Hospital from 1991 to 1994. He is a longstanding member of the medical advisory committee for the New England chapter of Crohn’s and Colitis Foundation of America.
Dr. Rifat Pamukcu was a Founder, Director and CSO of Cell Pathways, Inc.(CPI), an emerging pharmaceutical company acquired by OSI Pharmaceuticals. He directed the basic science, preclinical drug development, clinical research, regulatory programs, and various aspects of chemical scale-up and manufacturing over the course of decade. While at CPI, he led the development of exisulind, an oral apoptosis modulator and phosphodiesterase inhibitor, for the treatment of Familial Adenomatous Polyposis (FAP). He received his BA in Biology from The Johns Hopkins University and his MD degree from the University of Wisconsin School of Medicine. Dr. Pamukcu has authored over 110 journal articles, book chapters, and abstracts and is an inventor on over 280 issued or pending patents in the areas of drug discovery and development for cancer prevention, cancer treatment, and inflammatory bowel disease.
Dr. Rieder is an investigator at the Department of Pathobiology and an Associate Staff at the Department of Gastroenterology, Hepatology and Nutrition at the Cleveland Clinic, Cleveland. His clinical focus is patients with inflammatory bowel diseases (IBD) with a special emphasis on the field of pathogenesis, prediction and therapy of IBD.
Dr. Rieder has published more than 60 articles and book chapters and has been recognized for his expertise and he serves on multiple committees, speakers’ panels, steering committees and editorial boards. He is a member of the European Crohn’s and Colitis Organization (ECCO), the German Gastroenterology Association, the American Gastroenterology Association, the America Physiological Society, the American College of Physicians, and the Crohn’s and Colitis Foundation. He is the associate editor of Clinical and Translational Gastroenterology, section editor of Annals of Gastroenterology, on the editorial boards of the Journal of Crohn’s and Colitis, Inflammatory Bowel Diseases, BMC Gastroenterology, American Journal of Physiology: Gastrointestinal and Liver Physiology and Gastroenterology and Hepatology Journal. Dr. Rieder is the senior author of the new ECCO guidelines for Ulcerative colitis, the first author of the ECCO consensus on Fibrostenosing IBD and co-author of the new ECCO guidelines in Crohn’s disease.
He received his medical degree from the Ludwig-Maximilians-University Medical School in Germany. He underwent training in Internal Medicine / Gastroenterology at the Klinik und Poliklinik für Innere Medizin I, Universitätsklinikum Regensburg, Germany and a residency in Internal Medicine and fellowship in Gastroenterology, Hepatology and Nutrition at the Cleveland Clinic in Cleveland, Ohio. Dr. Rieder has performed research fellowships at Harvard Medical School and the Cleveland Clinic.